Last updated: August 11, 2026
Erythromycin ethylsuccinate is a mature, off-patent macrolide marketed primarily as an oral pediatric suspension and, in some markets, as tablets or capsules. Its commercial profile is defined by low unit prices, multiple generic suppliers, limited patent protection, and intermittent demand from pediatric and penicillin-allergic patients. Product-level revenue is not publicly disclosed, but the drug’s long-term financial trajectory is likely flat to declining, with temporary volume and pricing increases during antibiotic shortages.
What is the current market position of erythromycin ethylsuccinate?
Erythromycin ethylsuccinate is an oral ester prodrug of erythromycin. It has been used for respiratory-tract infections, skin and soft-tissue infections, pertussis, diphtheria, and other susceptible bacterial infections. The formulation is especially relevant when an oral liquid is needed or when a clinician selects a macrolide for a patient unable to take penicillin-based therapy.
The product competes with:
- Azithromycin
- Clarithromycin
- Erythromycin base
- Erythromycin stearate
- Penicillin V and amoxicillin
- Cephalexin and other oral beta-lactams
- Therapeutic alternatives selected according to local resistance patterns
The principal commercial distinction is the oral liquid format. Erythromycin ethylsuccinate suspension can retain demand in pediatric and institutional settings even when tablet and capsule demand is weak.
| Market factor |
Effect on erythromycin ethylsuccinate |
| Generic status |
Creates sustained price pressure |
| Pediatric suspension demand |
Supports a specialized residual market |
| Taste and gastrointestinal tolerability |
Limits prescribing relative to newer macrolides |
| Antibiotic stewardship |
Restricts use to selected indications |
| Supply disruptions |
Can create short-term volume and price spikes |
| Resistance |
Reduces use in several infectious-disease settings |
| Limited patent protection |
Lowers barriers to entry |
What is the financial trajectory for erythromycin ethylsuccinate?
The financial trajectory is best characterized as mature, fragmented, and low-growth. No publicly reported company discloses standalone global revenue for erythromycin ethylsuccinate. Generic manufacturers typically report revenue by business segment or product portfolio rather than by individual low-volume medicine.
The product’s economic profile has four stages:
- Brand-era commercialization generated higher prices and stronger margins.
- Generic entry reduced average selling prices and shifted purchasing power to wholesalers, group purchasing organizations, hospitals, and pharmacies.
- Long-term demand stabilized at a lower level because the product retained niche use in oral suspension and selected antibiotic indications.
- Shortage events can produce temporary revenue increases, but they do not create durable pricing power.
A reasonable commercial model is:
| Period |
Financial condition |
Main driver |
| Before broad generic competition |
Higher pricing and brand margins |
Brand positioning and limited competition |
| Early generic period |
Rapid price erosion |
Multiple ANDA suppliers |
| Mature generic period |
Low-margin recurring sales |
Residual clinical demand |
| Supply-constrained periods |
Temporary price and volume expansion |
Competitor shortages or manufacturing interruptions |
| Long-term outlook |
Flat to declining baseline |
Stewardship, substitution, and aging product |
The most valuable presentation is usually the oral suspension rather than standard solid oral dosage forms. Liquid antibiotics have more complex manufacturing, packaging, reconstitution, stability, and taste-masking requirements. Those constraints can reduce the number of reliable suppliers, even when the underlying active ingredient has no meaningful patent barrier.
How large is the erythromycin ethylsuccinate market?
Public FDA and manufacturer sources do not provide a reliable standalone market-size figure for erythromycin ethylsuccinate. Commercial prescription databases may contain product-level volume and sales data, but those datasets are generally subscription-based.
The addressable market is constrained by several factors:
- Erythromycin is an older macrolide with more gastrointestinal adverse effects than azithromycin and clarithromycin.
- Prescribers often favor newer macrolides because of dosing convenience and tolerability.
- Antibiotic stewardship programs discourage unnecessary macrolide use.
- Resistance patterns limit effectiveness in some respiratory pathogens.
- Treatment guidelines frequently prefer beta-lactams or other agents for common infections.
The remaining demand is concentrated in pediatric oral suspension, selected respiratory infections, pertussis-related treatment or prophylaxis, and patients with specific allergy or intolerance profiles. CDC treatment guidance continues to identify macrolides as relevant for selected infections, but drug choice depends on the organism, indication, local resistance, age, pregnancy status, and patient-specific factors (Centers for Disease Control and Prevention, 2021).
What FDA formulations are approved for erythromycin ethylsuccinate?
The principal FDA-regulated commercial format is the oral suspension or granules-for-reconstitution product. Historical products have also included tablets and capsules.
Oral suspension
The suspension is the commercially important formulation because it serves pediatric and swallowing-limited patients. Product economics depend on:
- Active ingredient potency after reconstitution
- Uniformity of dose throughout the bottle
- Stability during the labeled storage period
- Palatability and taste masking
- Reconstitution instructions
- Packaging and measuring-device accuracy
DailyMed labeling for erythromycin ethylsuccinate products identifies dosing by erythromycin-equivalent content and describes the indications, contraindications, warnings, and storage requirements for the relevant product (National Library of Medicine, n.d.).
Tablets and capsules
Solid oral dosage forms face stronger substitution from other macrolides and antibiotic classes. They also have fewer formulation barriers and are more exposed to generic price competition.
Erythromycin ethylsuccinate versus other erythromycin salts
Erythromycin ethylsuccinate should not be treated as commercially interchangeable with every erythromycin formulation. The salt or ester affects pharmacokinetics, dosage form, tolerability, and manufacturing requirements. Product selection must follow the approved label and applicable substitution rules.
What patents protect erythromycin ethylsuccinate?
No meaningful composition-of-matter patent barrier is expected for erythromycin ethylsuccinate. The active ingredient and its conventional oral dosage forms have been commercially available for decades.
The relevant protection categories are:
| Protection category |
Current commercial significance |
| Composition-of-matter patent |
Expired or commercially irrelevant |
| Conventional tablet patent |
No material barrier expected |
| Oral suspension formulation patent |
Any historical protection would generally be expired |
| Method-of-use patent |
Limited practical value for a mature broad-spectrum antibiotic |
| Manufacturing patent |
Potentially relevant only if tied to a specific process or quality attribute |
| Trade secret |
May protect process know-how but does not prevent generic approval |
| Device or packaging patent |
Could protect a measuring or delivery feature, not the active ingredient |
The FDA Orange Book is the primary source for approved drug products and listed patent or exclusivity information. For a mature erythromycin ethylsuccinate product, the commercial risk assessment is driven more by ANDA competition, manufacturing reliability, and supply-chain execution than by Orange Book patent enforcement (U.S. Food and Drug Administration, n.d.-a).
What is the Orange Book status of erythromycin ethylsuccinate?
Erythromycin ethylsuccinate products are evaluated through the FDA’s approved-drug and abbreviated-approval framework. Generic manufacturers generally rely on ANDAs that demonstrate bioequivalence to the applicable reference product rather than repeat full clinical efficacy trials.
The practical Orange Book considerations are:
- Whether a specific reference-listed drug remains active
- Whether a listed product is a prescription product or has been discontinued
- Whether any patents or exclusivities remain listed
- Whether a generic product has an AB-equivalence rating
- Whether the relevant dosage form and strength have approved ANDA competitors
Because the active ingredient is old and the market is genericized, any current Orange Book listing is unlikely to create a durable exclusivity position. The commercial review must be performed at the individual strength and dosage-form level because suspension concentrations and solid oral products can have different reference products and competitors.
When does erythromycin ethylsuccinate lose exclusivity?
Erythromycin ethylsuccinate has already lost the exclusivity that would support a branded monopoly. The key patent and regulatory exclusivity periods expired long ago relative to the current market.
There is no credible basis for treating erythromycin ethylsuccinate as a future patent-cliff product. Its current commercial exposure comes from ongoing generic competition rather than an upcoming loss of exclusivity.
The relevant timing risk is therefore supply-related:
- A manufacturer exits the market.
- A contract manufacturer experiences a quality failure.
- An active pharmaceutical ingredient supplier is disrupted.
- A pediatric suspension competitor enters shortage.
- Hospitals or pharmacies temporarily shift purchasing to available suppliers.
These events can alter pricing and market share without changing the underlying patent position.
Which companies are competing in erythromycin ethylsuccinate?
Competition has historically included branded and generic manufacturers of erythromycin ethylsuccinate oral suspension and other erythromycin products. The exact supplier set changes by strength, country, formulation, and time.
The branded product EryPed has been associated with Arbor Pharmaceuticals. Arbor’s products and assets later became part of a broader transaction and portfolio structure involving KVK-Tech. Product ownership and marketing rights should be verified against the current FDA label, National Drug Code records, and manufacturer information because ownership can change without altering the active ingredient’s approval status.
The competitive landscape is fragmented:
| Competitor type |
Commercial position |
| Branded legacy product |
Limited pricing power; may retain recognition in pediatric care |
| Generic oral-suspension supplier |
Competes on price, availability, and contracting |
| Generic tablet or capsule supplier |
Faces intense substitution and lower differentiation |
| Alternative macrolide manufacturer |
Competes on dosing convenience and tolerability |
| Beta-lactam supplier |
Captures first-line use in many infections |
What generic entry risks exist for erythromycin ethylsuccinate?
Generic entry risk is high in principle because patent protection is not a meaningful barrier. In practice, the number of dependable suppliers may be lower than the number of approved or historically marketed products.
Regulatory and manufacturing barriers
An ANDA applicant must satisfy requirements for:
- Pharmaceutical equivalence
- Bioequivalence
- Chemistry, manufacturing, and controls
- Microbial quality
- Stability
- Container-closure performance
- Labeling
- Facility compliance
For oral suspensions, manufacturing execution is more difficult than for a simple immediate-release tablet. Particle-size distribution, suspension uniformity, sedimentation, redispersibility, preservative control, and palatability can affect commercial success. FDA manufacturing-quality standards apply even when the medicine is clinically old (U.S. Food and Drug Administration, n.d.-b).
Launch scenarios
| Scenario |
Likely effect |
| New generic tablet launch |
Significant price erosion with limited market expansion |
| New pediatric suspension launch |
Moderate price pressure; potential share capture from incumbents |
| Incumbent supplier exit |
Temporary share and price gains for remaining suppliers |
| Broad antibiotic shortage |
Short-term demand increase, followed by normalization |
| Product quality recall |
Rapid substitution and possible contract losses |
What patent litigation and Paragraph IV challenges affect the product?
No material current U.S. patent-litigation risk is identified for erythromycin ethylsuccinate based on its mature generic status and the absence of a commercially meaningful patent estate.
Paragraph IV litigation is therefore unlikely to be the central market issue. A Paragraph IV certification challenges listed patents in an ANDA context. For erythromycin ethylsuccinate, the more relevant legal questions are likely to involve:
- Product-specific patent listings
- Labeling disputes
- Manufacturing-quality enforcement
- Drug-shortage allocation
- Contracting and distribution rights
- Product-liability claims
The absence of a meaningful patent dispute does not eliminate regulatory risk. FDA inspections, recalls, warning letters, and manufacturing interruptions can have a greater financial impact than patent litigation in this product category.
What licensing deals affect erythromycin ethylsuccinate?
No major publicly disclosed licensing transaction appears to establish a new proprietary erythromycin ethylsuccinate franchise. The product is more likely to move through asset purchases, portfolio transfers, contract manufacturing, or marketing-rights arrangements than through high-value research licensing.
Potential transaction value is concentrated in:
- An established pediatric brand
- An approved suspension product
- A validated manufacturing source
- Existing pharmacy and hospital contracts
- Reliable supply during competitor shortages
The commercial value of such rights depends on net pricing and supply reliability rather than patent duration.
How does erythromycin ethylsuccinate compare with azithromycin?
| Attribute |
Erythromycin ethylsuccinate |
Azithromycin |
| Market maturity |
Very mature |
Mature but commercially stronger |
| Typical dosing convenience |
Less favorable |
More favorable |
| Pediatric liquid relevance |
High in selected products |
High |
| Gastrointestinal tolerability |
Generally less favorable |
Often more favorable |
| Patent protection |
Expired |
Core patents expired; product-specific issues may vary |
| Generic competition |
High |
High |
| Differentiation |
Formulation and availability |
Dosing, persistence, and prescriber familiarity |
| Long-term growth |
Low |
More resilient residual demand |
Azithromycin has generally captured prescribing from older erythromycin products because of shorter treatment courses and more convenient dosing. Erythromycin ethylsuccinate retains a niche where clinical preference, age, formulation availability, or specific treatment guidance supports its use.
What is the geographic coverage of erythromycin ethylsuccinate?
Erythromycin is marketed internationally, but erythromycin ethylsuccinate availability varies substantially by country. Regulatory approval, brand ownership, formulation concentration, and generic supply differ across the United States, Europe, Canada, Australia, and emerging markets.
The United States market is governed by FDA approval, ANDA competition, Orange Book status, National Drug Code listings, and U.S. drug-shortage reporting. International markets may use different reference products and may not recognize the same patents, trademarks, or regulatory classifications.
Geographic risk is therefore operational rather than patent-driven. A manufacturer may have reliable supply in one market while facing shortages, discontinuation, or limited registration in another.
How strong is the erythromycin ethylsuccinate patent estate?
The patent estate is weak from an exclusivity perspective. The active ingredient is old, conventional formulations are established, and the commercial market has long operated through generic competition.
A residual patent or proprietary position could still have value if it protects:
- A differentiated pediatric suspension
- A stable high-concentration formulation
- A taste-masking system
- A novel package or dosing device
- A manufacturing process that improves yield or impurity control
Such protection would generally support incremental differentiation, not a broad monopoly over erythromycin ethylsuccinate.
Key Takeaways
- Erythromycin ethylsuccinate is a mature, genericized macrolide with no meaningful composition-of-matter exclusivity.
- The most defensible commercial niche is pediatric oral suspension.
- Product-level revenue is not publicly reported, but the baseline financial trajectory is flat to declining.
- Shortages can produce temporary price and volume increases without changing long-term market structure.
- Generic entry risk is high, while patent-litigation risk is low.
- Manufacturing quality, palatability, suspension stability, and supply reliability matter more than patent ownership.
- Azithromycin and clarithromycin have reduced erythromycin’s role in many outpatient settings.
- Brand or portfolio value depends on contracts, formulation execution, and dependable supply rather than intellectual-property duration.
FAQs
Is erythromycin ethylsuccinate still commercially available?
Availability depends on the specific strength, dosage form, manufacturer, and country. Oral suspension products may remain commercially relevant even when individual suppliers discontinue or temporarily restrict distribution.
Is erythromycin ethylsuccinate interchangeable with azithromycin?
No. The products have different active ingredients, dosing schedules, pharmacokinetics, labeling, and clinical-use profiles. Substitution requires an appropriate prescribing decision.
Can a company obtain FDA approval for a new erythromycin ethylsuccinate generic?
Yes. A manufacturer may pursue an ANDA if it can demonstrate pharmaceutical equivalence, bioequivalence, manufacturing quality, and compliance with FDA requirements for the applicable reference product.
Does erythromycin ethylsuccinate have biosimilar risk?
No. Biosimilar rules apply to biologic products. Erythromycin ethylsuccinate is a chemically synthesized small-molecule drug and faces generic, not biosimilar, competition.
What would increase the value of an erythromycin ethylsuccinate product?
The strongest value drivers would be reliable pediatric-suspension supply, a differentiated taste-masking profile, efficient manufacturing, hospital or pharmacy contracts, and the ability to maintain availability during competitor shortages.
References
-
Centers for Disease Control and Prevention. (2021). Sexually transmitted infections treatment guidelines, 2021. https://www.cdc.gov/std/treatment-guidelines/default.htm
-
National Library of Medicine. (n.d.). DailyMed: Erythromycin ethylsuccinate product labeling. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.-b). Abbreviated new drug application abbreviated approval process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
-
U.S. Food and Drug Administration. (n.d.-c). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages-index
